A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4
B cell immunity
COVID-19
Hemodialysis
Immune cell phenotyping
SARS-CoV-2
T cell immunity
Vaccine response
mRNA vaccine
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 03 2023
21 03 2023
Historique:
received:
08
08
2022
revised:
27
12
2022
accepted:
02
02
2023
pubmed:
3
3
2023
medline:
25
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4
Identifiants
pubmed: 36863335
pii: S2666-3791(23)00047-2
doi: 10.1016/j.xcrm.2023.100955
pmc: PMC9902290
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100955Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests C.T. serves as a consultant for Merck, Gilead, GSK, AstraZeneca, and Medicago.